Unchanged Testosterone Production Rates in Growth Hormone-Treated Healthy Men1

The effect of biosynthetic human GH on the production rates of testosterone was determined in healthy men (n = 7) using the stable isotope dilution technique and mass spectrometry. 1α,2α-d-Testosterone (20 μg/h) was infused for 10 h (0800–1800 h). Blood samples obtained at 20-min intervals from 1400–1800 h were pooled during two 2-h periods. Subsequently, each volunteer received a daily dose of biosynthetic human GH (4 IU/day sc) for 7 days. This resulted in a rise in plasma concentrations of somatomedin-C from, basal, 0.67 ± 0.13 U/mL to 1.20± 0.2 U/mL on day 7 (P < 0.0001). Testosterone production rates (basal: 209.9 ± 31.0 μg/h) were unchanged by treatment with GH (day 7: 192.2 ± 30.1 μg/h). In healthy men, short-term treatment with sc GH does not influence endogenous testosterone production rates.

Download Full-text

Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets

Acta Endocrinologica ◽

10.1530/eje-09-0433 ◽

2010 ◽

Vol 162 (1) ◽

pp. 75-83 ◽

Cited By ~ 22

Author(s):

Solrun Vidarsdottir ◽

Ferdinand Roelfsema ◽

Trea Streefland ◽

Jens J Holst ◽

Jens F Rehfeld ◽

...

Keyword(s):

Weight Gain ◽

Peptide Yy ◽

Hormone Secretion ◽

Gut Hormones ◽

Term Treatment ◽

Short Term ◽

Short Term Treatment ◽

Healthy Men ◽

Gut Hormone ◽

Glucagon Like Peptide 1

BackgroundTreatment with olanzapine (atypical antipsychotic drug) is frequently associated with various metabolic anomalies, including obesity, dyslipidemia, and diabetes mellitus. Recent data suggest that olanzapine orally disintegrating tablets (ODT), which dissolve instantaneously in the mouth, might cause less weight gain than olanzapine standard oral tablets (OST).Design and methodsTen healthy men received olanzapine ODT (10 mg o.d., 8 days), olanzapine OST (10 mg o.d., 8 days), or no intervention in a randomized crossover design. At breakfast and dinner, blood samples were taken for measurement of pancreatic polypeptide, peptide YY, glucagon-like peptide-1, total glucagon, total ghrelin, and cholecystokinin (CCK) concentrations.ResultsWith the exception of pre- and postprandial concentration of ghrelin at dinner and preprandial CCK concentrations at breakfast, which were all slightly increased (respectivelyP=0.048,P=0.034 andP=0.042), olanzapine did not affect gut hormone concentrations. Thus, olanzapine ODT and OST had similar effects on gut hormone secretion.ConclusionShort-term treatment with olanzapine does not have major impact on the plasma concentration of gut hormones we measured in healthy men. Moreover, despite pharmacological difference, gut hormone concentrations are similar during treatment with olanzapine ODT and OST. The capacity of olanzapine to induce weight gain and diabetes is unlikely to be caused by modulation of the secretion of gut hormones measured here. We cannot exclude the possibility that olanzapine's impact on other gut hormones, to impair insulin sensitivity and stimulate weight gain, exists.

Download Full-text

Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men

Metabolism ◽

10.1053/meta.2002.31332 ◽

2002 ◽

Vol 51 (4) ◽

pp. 531-536 ◽

Cited By ~ 40

Author(s):

Bernd Fruehwald-Schultes ◽

Kerstin M. Oltmanns ◽

Barbara Toschek ◽

Stefan Sopke ◽

Werner Kern ◽

...

Keyword(s):

Body Weight ◽

Body Fat ◽

Fat Content ◽

Term Treatment ◽

Normal Weight ◽

Short Term ◽

Short Term Treatment ◽

Serum Leptin ◽

Healthy Men ◽

Body Fat Content

Download Full-text

Plasma Concentrations of Diazepam, Nordiazepam and Amylobarbitone after Short-term Treatment of Anxious Patients

Pharmacopsychiatry ◽

10.1055/s-0028-1094564 ◽

1978 ◽

Vol 11 (02) ◽

pp. 68-75 ◽

Cited By ~ 11

Author(s):

M. Tansella ◽

Ch. Zimmermann Tansella ◽

L. Ferrario ◽

L. Preziati ◽

G. Tognoni ◽

...

Keyword(s):

Plasma Concentrations ◽

Term Treatment ◽

Short Term ◽

Short Term Treatment

Download Full-text

Failure of short-term hyperinsulinemia to affect testosterone production rates in healthy men

Metabolism ◽

10.1016/s0026-0495(98)90204-9 ◽

1998 ◽

Vol 47 (1) ◽

pp. 119-120 ◽

Cited By ~ 1

Author(s):

H. Vierhapper ◽

P. Nowotny ◽

W. Waldhäusl

Keyword(s):

Production Rates ◽

Short Term ◽

Healthy Men ◽

Testosterone Production

Download Full-text

Effect of Enoxaparin on Homocysteine Concentration in Warfarin-Treated Patients

Annals of Pharmacotherapy ◽

10.1345/aph.1a460 ◽

2002 ◽

Vol 36 (9) ◽

pp. 1355-1359 ◽

Cited By ~ 1

Author(s):

Yael Haviv ◽

Aaron Lubetsky ◽

Ben-Ami Sela ◽

David Ezra ◽

David Olchovsky

Keyword(s):

Medical Center ◽

Tertiary Care ◽

Plasma Concentrations ◽

Term Treatment ◽

Term Therapy ◽

Weekly Dose ◽

Short Term ◽

Short Term Treatment ◽

Homocysteine Concentration ◽

Plasma Thcy

BACKGROUND: Elevated plasma total homocysteine (tHcy) concentration is an emerging independent risk factor for hypercoagulability states and cardiovascular diseases. Many disease states and various drug treatment regimens are known to affect plasma tHcy concentration. OBJECTIVE: To examine the effect of short-term treatment with the low-molecular-weight heparin enoxaparin on plasma tHcy concentrations. METHODS: A prospective study was conducted in an outpatient anticoagulation clinic set in a tertiary care referral medical center. Subjects included twenty-four consecutive patients treated with warfarin who were scheduled for short-term enoxaparin treatment. Fasting plasma tHcy concentrations were measured before and after 3 days of enoxaparin treatment in patients who began short-term therapy with enoxaparin because of temporary inadequate anticoagulation (international normalized ratio <1.5). The main outcome measures were the difference in tHcy concentration between baseline and after enoxaparin treatment. RESULTS: tHcy plasma concentrations decreased in most patients (n = 21), did not change in 2, and increased in 1 patient after 3 days of enoxaparin treatment. The decline of tHcy was statistically significant: from 9.8 ± 3.4 to 7.6 ± 2.6 μmol/L (mean ± SD; p < 0.005). This decline was more prominent in patients with baseline tHcy plasma concentrations above the normal range compared with patients with normal baseline concentrations. Six patients in whom a third sample was obtained 15–30 days after the last enoxaparin injection developed decreased mean tHcy plasma concentrations: from 9.1 ± 3.0 μmol/L at baseline to 6.4 ± 2.0 μmol/L on day 3 and further to 5.7 ± 1.8 μmol/L on days 15–30. No relation was found between age, gender, treatment indication, and average weekly dose of warfarin to the presence or magnitude of tHcy plasma concentration decline. CONCLUSIONS: Short-term treatment with enoxaparin reduces plasma tHcy concentrations. Further studies are needed to clarify the mechanism and the clinical significance of enoxaparin's effect.

Download Full-text